Kureha Corporation Lifts FY2027 Forecast on Profitability Recovery
Kureha Corporation (TSE:4023), a mid-sized Japanese chemical manufacturer specializing in fluorine resins, high-performance materials, and plastic-alternative compounds, swung to a net loss of JPY 10.6bn in fiscal year 2026 (ended March 2026) despite nearly flat revenue, signaling a severe margin compression that management expects to reverse sharply in the coming year.
The company reported revenue of JPY 161.7bn, down just 0.2% year-over-year, but operating profit collapsed to a loss of JPY 18.6bn from a profit of JPY 9.4bn in the prior year—a 28.0bn swing that drove the operating margin to -11.5% from +5.8%. Ordinary income (keijo rieki, Japan’s recurring profit metric that includes non-operating items) fell to JPY -18.3bn, and net profit to JPY -10.6bn. The deterioration occurred despite stable operating cash flow of JPY 28.0bn, suggesting the loss reflects structural cost pressures rather than demand collapse.
Key Financials (FY2026)
| Metric | FY2026 | FY2025 | Change |
|---|---|---|---|
| Revenue | JPY 161.7bn | JPY 162.0bn | -0.2% |
| Operating Profit | JPY -18.6bn | JPY 9.4bn | Loss swing |
| Ordinary Income | JPY -18.3bn | JPY 10.2bn | Loss swing |
| Net Profit | JPY -10.6bn | JPY 7.9bn | Loss swing |
| Operating Margin | -11.5% | +5.8% | -17.3 pts |
Business Overview
Kureha Corporation manufactures specialty chemicals and advanced materials, with particular strength in fluorine resins used in semiconductors, automotive, and industrial applications. The company is also investing in plastic-alternative materials and pharmaceutical/agrochemical compounds as part of a strategic pivot toward higher-margin, sustainability-focused products.
Analysis: Margin Compression and Capital Deterioration
The FY2026 result represents a dramatic reversal from the prior year’s profitability. Revenue stagnation combined with a JPY 28.0bn operating profit swing indicates that the loss was driven by cost structure misalignment—likely a combination of elevated raw material costs, unfavorable product mix, or one-time charges related to restructuring or asset impairments. The company did not disclose a formal earnings revision (gyoseki shussei), suggesting these headwinds either materialized gradually or were absorbed within management’s original guidance.
A concerning secondary indicator is the equity ratio (jiko shihon hiritsu), which contracted from 60.6% to 48.8%—an 11.8 percentage point decline that reflects both the net loss and a JPY 44.1bn reduction in shareholders’ equity. This was partly offset by the company’s execution of a share buyback program, reducing outstanding shares by approximately 10%, a typical Japanese capital management tactic to support earnings per share despite underlying profit weakness.
Operating cash flow remained resilient at JPY 28.0bn, nearly matching the prior year’s JPY 29.5bn, but this stability warrants scrutiny. In a loss-making year, sustained operating cash generation often reflects working capital management (inventory drawdowns or receivables collection) rather than underlying business strength. The company’s cash position improved to JPY 29.7bn from JPY 21.5bn, supported by lower capital expenditure and reduced dividend outflows.
Next Year Guidance
| Metric | FY2027 Forecast | vs. FY2026 | Change |
|---|---|---|---|
| Revenue | JPY 172.0bn | JPY 161.7bn | +6.4% |
| Operating Profit | JPY 11.0bn | JPY -18.6bn | Return to profit |
| Ordinary Income | JPY 10.5bn | JPY -18.3bn | Return to profit |
| Net Profit | JPY 7.5bn | JPY -10.6bn | Return to profit |
Management projects a sharp recovery, with revenue rising 6.4% to JPY 172.0bn and operating profit rebounding to JPY 11.0bn—implying an operating margin of approximately 6.4%, slightly above the company’s historical mid-cycle performance. The forecast assumes a return to profitability across all metrics and signals confidence that FY2026’s losses were cyclical rather than structural. However, the magnitude of the turnaround—from an 11.5% operating loss to a 6.4% operating margin—is ambitious and hinges on successful cost normalization and demand stabilization.
What to Watch
Segment profitability disclosure: The earnings flash report (kessan tanshin) lacks detailed segment-level operating profit data, leaving investors unable to identify which business units drove the FY2026 loss or are expected to lead the recovery. Clarity on fluorine resin, high-performance materials, and pharmaceutical/agrochemical segment performance will be critical to validating the FY2027 forecast.
Cash conversion and working capital: With operating cash flow stable despite significant losses, monitor whether FY2027 profitability translates into genuine cash earnings or reflects continued working capital optimization. A return to normalized inventory and receivables levels could pressure cash flow even if accounting profits recover.
Dividend sustainability and capital allocation: The company plans to resume dividends in FY2027 under a target equity dividend payout ratio (DOE) of 5%, a shift toward capital-based rather than earnings-based distribution. Confirmation of this policy and its consistency with the profit recovery forecast will signal management confidence in the turnaround.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.